	US 11,732,266 B2
	RNAi constructs for inhibiting ASGR1 expression and methods of use thereof
Michael Ollmann, San Carlos, CA (US); Yang Li, Mountain View, CA (US); Jun Zhang, Foster City, CA (US); Oliver Homann, Berkeley, CA (US); Leslie P. Miranda, Thousand Oaks, CA (US); Justin K. Murray, Moorpark, CA (US); Bin Wu, Thousand Oaks, CA (US); Oh Kyu Yoon, Pacifica, CA (US); John Gordon Allen, Newbury Park, CA (US); Chawita Netirojjanakul, Longmont, CO (US); and Yuan Cheng, Newbury Park, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US)
Filed on Oct. 26, 2020, as Appl. No. 17/80,771.
Application 17/080,771 is a continuation of application No. 16/328,221, granted, now 10,870,856, previously published as PCT/US2017/048757, filed on Aug. 25, 2017.
Claims priority of provisional application 62/380,216, filed on Aug. 26, 2016.
Prior Publication US 2021/0108212 A1, Apr. 15, 2021
Int. Cl. C12N 15/113 (2010.01); A61P 9/10 (2006.01); A61P 3/06 (2006.01); C07K 16/28 (2006.01)

CPC C12N 15/1138 (2013.01) [A61P 3/06 (2018.01); A61P 9/10 (2018.01); C07K 16/2851 (2013.01); C07K 2317/526 (2013.01); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/317 (2013.01); C12N 2310/321 (2013.01); C12N 2310/332 (2013.01); C12N 2310/351 (2013.01); C12N 2310/3513 (2013.01)]

34 Claims

1. An RNAi construct comprising a sense strand, an antisense strand, and a ligand, wherein the antisense strand comprises a region having a sequence that is complementary to an ASGR1 mRNA sequence, and wherein said region comprises at least 15 contiguous nucleotides of SEQ ID NO: 2323.